Home › Trials › NCT05552976

Evaluating Mezigdomide with Carfilzomib and Dexamethasone for Multiple Myeloma

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

Phase 3 Interventional Bristol-Myers Squibb · NCT05552976

This study is testing if adding Mezigdomide to the standard treatment of Carfilzomib and Dexamethasone can help people with relapsed or refractory multiple myeloma feel better.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment525 (estimated)
Ages18 Years and up
SexAll
SponsorBristol-Myers Squibb Industry-sponsored
Locations217 sites (Mobile, Alabama and 216 other locations)
Trial IDNCT05552976 on ClinicalTrials.gov

What this trial studies

This study aims to compare the effectiveness of Mezigdomide in combination with Carfilzomib and Dexamethasone against the standard treatment of Carfilzomib and Dexamethasone in patients with relapsed or refractory multiple myeloma. Participants must have measurable disease and a history of prior anti-myeloma therapy. The study is designed to assess the potential benefits of the new combination therapy in improving patient outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults with a documented diagnosis of multiple myeloma who have received at least one prior line of anti-myeloma therapy.

Not a fit: Patients who have not received prior treatment with lenalidomide or anti-CD38 monoclonal antibodies may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a more effective option for patients with relapsed or refractory multiple myeloma.

How similar studies have performed: Other studies have shown promise with similar combination therapies in treating multiple myeloma, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.

i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.

ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.

iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels \> 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.

* Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, \[with or without\] hematopoietic stem cell transplant, (with or without) consolidation, and/or \[with or without\] maintenance therapy).
* Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received \< 2 cycles are still eligible).
* Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
* Participant must have documented disease progression during or after their last antimyeloma regimen.

Exclusion Criteria

* Participant who has had prior treatment with mezigdomide or carfilzomib.
* Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

Mobile, Alabama and 216 other locations

+167 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Relapsed or Refractory Multiple MyelomaBMS-986348CC-92480CarfilzomibDexamethasoneMultiple MyelomaMezigdomide
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.